Windtree Therapeutics Inc /De/ financial data

Symbol
WINT on Nasdaq, WINTW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
2600 Kelly Road, Suite 100, Warrington, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Former names
DISCOVERY LABORATORIES INC /DE/ (to 4/18/2016), ANSAN PHARMACEUTICALS INC (to 7/21/1997), ANSAN INC (to 5/15/1996)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 188 % -23.9%
Debt-to-equity 267 % +20.1%
Return On Equity -62.9 % +76%
Return On Assets -17.1 % +78.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.18 M shares +910%
Common Stock, Shares, Outstanding 510 K shares -43.9%
Entity Public Float 6.2 M USD -32.6%
Common Stock, Value, Issued 1 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 465 K shares +869%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.18 M USD +28%
Operating Income (Loss) -20.8 M USD +44%
Nonoperating Income (Expense) 15 M USD +2268%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 10.3 M USD
Income Tax Expense (Benefit) 114 K USD
Net Income (Loss) Attributable to Parent -5.96 M USD +83.1%
Earnings Per Share, Basic 102 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.55 M USD -39.9%
Assets, Current 3.34 M USD -36.1%
Property, Plant and Equipment, Net 162 K USD -32.2%
Operating Lease, Right-of-Use Asset 1.34 M USD -22.7%
Intangible Assets, Net (Excluding Goodwill) 9.7 M USD -42.9%
Goodwill 0 USD -100%
Assets 30.1 M USD -14.4%
Accounts Payable, Current 1.69 M USD +124%
Employee-related Liabilities, Current 64 K USD -48%
Accrued Liabilities, Current 2.13 M USD +31.1%
Liabilities, Current 4.99 M USD +80.4%
Deferred Income Tax Liabilities, Net 4.86 M USD -4.37%
Operating Lease, Liability, Noncurrent 1.04 M USD -31.3%
Other Liabilities, Noncurrent 3.8 M USD 0%
Liabilities 14.7 M USD -47.9%
Retained Earnings (Accumulated Deficit) -835 M USD -0.72%
Stockholders' Equity Attributable to Parent 15.4 M USD +119%
Liabilities and Equity 30.1 M USD -14.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.95 M USD -17%
Net Cash Provided by (Used in) Financing Activities 1.03 M USD +75%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120 M shares 0%
Common Stock, Shares, Issued 510 K shares -43.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.91 M USD +0.78%
Deferred Tax Assets, Valuation Allowance 185 M USD -12.3%
Deferred Tax Assets, Gross 185 M USD -12.3%
Operating Lease, Liability 1.6 M USD -21.3%
Depreciation 21 K USD -8.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 1.78 M USD -23.9%
Property, Plant and Equipment, Gross 3.92 M USD +0.1%
Operating Lease, Liability, Current 446 K USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 570 K USD +1.79%
Lessee, Operating Lease, Liability, to be Paid, Year One 531 K USD +0.38%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 182 K USD -41.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 581 K USD +1.93%
Deferred Tax Assets, Operating Loss Carryforwards 159 M USD -14.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 97 K USD -83.3%
Additional Paid in Capital 853 M USD +1.71%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.24 M USD -52.2%
Interest Expense 51 K USD -1.92%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%